Opioid Tapering and Withdrawal Guidance

Similar documents
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline

Berkshire West Area Prescribing Committee Guidance

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

Rule Governing the Prescribing of Opioids for Pain

Analgesics: Management of Pain In the Elderly Handout Package

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Drug Name (specify drug) Quantity Frequency Strength

Drug Name (specify drug) Quantity Frequency Strength

Fighting the Good Fight: How to Convert Opioids Just Right!

Q&A: Opioid Prescribing for Chronic Non-Malignant Pain

Prescribing drugs of dependence in general practice, Part C

Supportive Care. End of Life Phase

Prior Authorization Guideline

Dose equivalent of fentanyl patch to oxycontin

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Opioid Management of Chronic (Non- Cancer) Pain

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Subject: Pain Management (Page 1 of 7)

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

10 mg hydrocodone equals how much oxycodone

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Persistent Pain Resources. Educational Slide Set

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Knock Out Opioid Abuse in New Jersey:

Location of initiative York Region Chronic Kidney Disease Program, Mackenzie Richmond Hill Hospital, Richmond Hill, ON

Pain Management Management in Hepatic Hepatic and and Renal Dysfunction

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline

Oxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5

EXTENDED RELEASE OPIOID DRUGS

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Equianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine

Proposed Revision to Med (i)

Update on OXYCODONE. what can primary care do about the problem? 8 BPJ Issue 44

DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*

Overview of Essentials of Pain Management. Updated 11/2016

Appropriate prescribing of Oxycodone for non-cancer pain in general practice

Recommendations in Opioid Prescribing Guidelines for Chronic Pain

NBPDP Drug Utilization Review Process Update

Shining a Light on MEDs Understanding morphine equivalent dose

See Important Reminder at the end of this policy for important regulatory and legal information.

Opioid Conversion Ratios - Guide to Practice 2010

Long Term Care Formulary HCD - 08

I. Chronic Pain Information Page 2-3. II. The Role of the Primary Care Physician in Chronic Pain Management Page 3-4

GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE

Revised 9/30/2016. Primary Care Provider Pain Management Toolkit

OPIOID IR COMBO DRUGS. Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Tramadolacetaminophen

PRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

E-Learning Module N: Pharmacological Review

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older

Regional Renal Training

CLINICAL POLICY DEPARTMENT: Medical

Oxycontin conversion to ms contin

Chronic Non Malignant Pain Opioid Guideline

Best Practice Statement ~ November The management of pain in patients with cancer

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control

Safe Prescribing of Drugs with Potential for Misuse/Diversion

July We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely, 7/14

Opioid Conversion Guidelines

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

See Important Reminder at the end of this policy for important regulatory and legal information.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Which is stronger 100 mg. tramadol or 5 mg oxycodone

is rarely visible, and communication about use of opioids for chronic pain patients is ad hoc and informal.

Opioid Pearls and Acute Pain Management

Acute pain management in opioid tolerant patients. Muhammad Laklouk

Welcome - we will begin the webinar shortly Please read the participation tips below:

30 mg codeine vs 5 mg hydrocodone

OPIOID PRESCRIBING BY ONTARIO DENTISTS

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

White Paper on. Prescription Drug Abuse

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

KANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998

GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE

Pain and the MGH Promise

Universal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?

PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS

Renal Palliative Care Last Days of Life

Analgesia in patients with impaired renal function Formulary Guidance

Guidelines for Management of Chronic Non- Malignant Pain

New Guidelines for Prescribing Opioids for Chronic Pain

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

Section I. Short-acting opioid Prior Authorization Criteria

See Important Reminder at the end of this policy for important regulatory and legal information.

Conversion from oxycodone to ms contin

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

Transcription:

Opioid Tapering and Withdrawal Guidance 1. Introduction It is important to recognise the need to withdraw opioid regimens where the patient is deriving no therapeutic benefit. According the Royal College or Anaesthetists, Faculty of Pain Medicine, the dose above which harms outweigh benefits is 120mg oral morphine equivalent/24hours. Increasing opioid load above this dose is unlikely to yield further benefits but exposes the patient to increased harm. [1] 2. Consider tapering and withdraw opioid regimens if: The opioid is not providing useful pain relief: The underlying painful condition resolves The patient receives a definitive pain relieving intervention (e.g. joint replacement) The patient develops intolerable side effects There is strong evidence that the patient is diverting his/her medications to others The rationale for opioid taper and withdrawal must be clearly documented in the patient s record 3. Prior to tapering and withdrawing the regimen the following should be considered: Does the patient require discussion with secondary care prior to opioid tapering and withdrawal? o Discuss the patient with specialist services if the patient is receiving >300mg morphine equivalent/24hours [1] Physical and mental health co-morbidities, including significant emotional trauma, should be considered before initiating a withdrawal o Consider referral to specialist outpatient services where significant comorbidities exist (see section 4) [1] Management of pain during the tapering of opioids: o Ensure appropriate doses of breakthrough medication or adjuvant analgesics are prescribed during the period of withdrawal. o Reassess need for opioid therapy if clinically relevant pain is experienced by the patient during the period of withdrawal Symptoms and signs of opioid withdrawal: o Symptomatic management of withdrawal effects should be initiated where appropriate e.g. diarrhoea Arrangements for follow-up including agreed prescribing responsibilities 4. Tapering and withdrawing opioids in primary care:

The decision to taper and withdraw an established opioid regimen needs to be discussed carefully with the patient including: Explanation of the rationale for stopping opioids including the potential benefits of opioid reduction (avoidance of long term harms and improvement in ability to engage in self-management strategies) Agreeing outcomes of opioid tapering Arrangements for monitoring and support during opioid taper Documented agreement of tapering schedule 5. Stopping opioids in collaboration with specialist services: Patients who are failing to derive benefit from large doses of opioids (greater than oral morphine equivalent of around 300mg/day) may need support from specialist services in order to reduce medication. [1] This must include detailed exploration of emotional and mental health history (including addiction). Opioid tapering and withdrawal when patients are taking high doses is more likely to succeed if patients emotional and mental health needs are identified and an appropriate plan for support established. [1] 6. Opioid tapering: The original dose of opioid can be tapered by 10% weekly [1] [2] The original total daily dose of the opioid to be tapered should be reduced by 10% every week (every seven days). In the case of modified-release regimens the total daily dose should be reduced by 10%, divided by two and given twice a day. Associated when required doses must be reduced accordingly (typically 1/6 of the total daily dose). A morphine tapering chart is included in section 7. Clinicians can determine the equivalent tapering regimens for alternative opioids by using the dose conversion table in section 6. 7. Equivalent doses of opioid analgesics [3] Analgesic Route Dose Morphine 10 mg Oxycodone Dose conversion from oxycodone to MORPHINE: 0.66 6.6 mg Dose conversion from MORPHINE to oxycodone: x 0.66

Hydromorphone Dose conversion from hydromorphone to MORPHINE: 0.2 Dose conversion from MORPHINE to hydromorphone: x 0.2 Tramadol Dose conversion from tramadol to MORPHINE: 10 Dose conversion from MORPHINE to tramadol: x 10 Codeine Dose conversion from codeine to MORPHINE: 10 Dose conversion from MORPHINE to codeine: x 10 2 mg 100 mg 100 mg Please note: this is only an approximate guide (doses may not correspond with those given in clinical practice); patients should be carefully monitored after any change in medication and dose adjustment may be required. = by mouth.

8. Opioid Tapering Chart Please note: all doses in the following chart has been rounded to the nearest 5mg for ease of administration. MR = modified release tablets/capsules and IR = immediate release tablets/capsules or liquid. Starting Dose (mg) Week 1 (mg) Week 2 (mg) Week 3 (mg) Week 4 (mg) Week 5 (mg) Week 6 (mg) Week 7 (mg) Week 8 (mg) Week 9 (mg) Total amount of MORPHINE to be supplied (mg) - not incuding PRN 24 hourly dose (MR) 120 110 95 85 70 60 50 35 25 10 3780 12 hourly dose (MR) - mane 60 55 45 40 35 30 25 15 15 5 12 hourly dose (MR) - nocte 60 55 50 45 35 30 25 20 10 5 THREE THOUSAND SEVEN HUNDRED AND EIGHTY MILIGRAMS PRN dose (IR) 20 20 15 15 10 10 10 5 5 0 MORPHINE EQUIVALENT 24 hourly dose (MR) 140 125 110 100 85 70 55 40 30 15 4410 12 hourly dose (MR) - mane 70 60 55 50 40 35 25 20 15 5 12 hourly dose (MR) - nocte 70 65 55 50 45 35 30 20 15 10 FOUR THOUSAND FOUR HUNDRED AND TEN MILIGRAMS PRN dose (IR) 25 20 20 15 15 10 10 5 5 0 24 hourly dose (MR) 160 145 130 110 95 80 65 50 30 15 5040 12 hourly dose (MR) - mane 80 70 65 55 45 40 30 25 15 5 12 hourly dose (MR) - nocte 80 75 65 55 50 40 35 25 15 10 FIVE THOUSAND AND FOURTY MILIGRAMS PRN dose (IR) 25 25 20 20 15 15 10 10 5 5 24 hourly dose (MR) 180 160 145 125 110 90 70 55 35 20 5670 12 hourly dose (MR) - mane 90 80 70 60 55 45 35 25 15 10 12 hourly dose (MR) - nocte 90 80 75 65 55 45 35 30 20 10 FIVE THOUSAND SIX HUNDRED AND SEVENTY MILGRAMS PRN dose (IR) 30 25 25 20 20 15 10 10 5 5 24 hourly dose (MR) 200 180 160 140 120 100 80 60 40 20 6300 12 hourly dose (MR) - mane 100 90 80 70 60 50 40 30 20 10 12 hourly dose (MR) - nocte 100 90 80 70 60 50 40 30 20 10 SIX THOUSAND THREE HUNDRED MILGRAMS PRN dose (IR) 35 30 25 25 20 15 15 10 5 5 24 hourly dose (MR) 220 200 175 155 130 110 90 65 45 20 6930 12 hourly dose (MR) - mane 110 100 85 75 65 55 45 30 20 10 12 hourly dose (MR) - nocte 110 100 90 80 65 55 45 35 25 10 SIX THOUSAND NINE HUNDRED AND THIRTY MILIGRAMS PRN dose (IR) 35 35 30 25 20 20 15 10 5 5 24 hourly dose (MR) 240 215 190 170 145 120 95 70 50 25 7560 12 hourly dose (MR) - mane 120 105 95 85 70 60 45 35 25 10 12 hourly dose (MR) - nocte 120 110 95 85 75 60 50 35 25 15 SEVEN THOUSAND FIVE HUNDRED AND SIXTY MILIGRAMS PRN dose (IR) 40 35 30 30 25 20 15 10 10 5 24 hourly dose (MR) 260 235 210 180 155 130 105 80 50 25 8190 12 hourly dose (MR) - mane 130 115 105 90 75 65 50 40 25 10 12 hourly dose (MR) - nocte 130 120 105 90 80 65 55 40 25 15 EIGHT THOUSAND ONE HUNDRED AND NINTY MILIGRAMS PRN dose (IR) 45 40 35 30 25 20 15 15 10 5 STOP 24 hourly dose (MR) 280 250 225 195 170 140 110 85 55 30 8820 12 hourly dose (MR) - mane 140 125 110 95 85 70 55 40 25 15 12 hourly dose (MR) - nocte 140 125 115 100 85 70 55 45 30 15 EIGHT THOUSAND EIGHT HUNDRED AND TWENTY MILIGRAMS PRN dose (IR) 45 40 35 35 30 25 20 15 10 5

References 1. Royal College of Anaesthetists, Faculty of Pain Medicine. Tapering and Stopping. Royal College of Anaesthetists. Accessed via http://www.rcoa.ac.uk/faculty-of-painmedicine/opioids-aware/structured-approach-to-prescribing/tapering-and-stopping [Accessed online: 25th October 2016]. 2. US National Centre for Injury Prevention and Control, Division of Unintentional Injury Prevention. Common Elements in Guidelines for Prescribing Opioids for Chronic Pain. US National Centre for Injury Prevention and Control. Accessed via: http://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_presc ribing_opioids-a.pdf [Accessed online: 25th October 2016]. 3. Royal Pharmaceutical Society, British National Formulary, Vol. 71, London: Pharmaceutical Press, 2016.